GabrielaSorianoHobbsMD

Oncology • Boston, MA

Hematologic Oncology

Physician

Join to view full profile

Dr. Hobbs is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Hobbs' full profile

Already have an account?

Office
55 Fruit St
# STREET1
Boston, MA 02114
Phone+1 617-724-1124

Summary

I am a board certified hematologist and oncologist. I am the clinical director of the adult leukemia service at MGH. My clinical and research focus is the treatment of patients with leukemia, specifically patients with myeloproliferative neoplasms.

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2011 - 2014
Brigham and Women's HospitalResidency, Internal Medicine, 2008 - 2011
Icahn School of Medicine at Mount SinaiClass of 2008

Certifications & Licensure

ME State Medical License 2020 - 2026
RI State Medical License 2021 - 2026
MA State Medical License 2010 - 2025
NH State Medical License 2021 - 2025
FL State Medical License 2021 - 2023
NY State Medical License 2011 - 2015
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Study of Regorafenib in Patients With Advanced Myeloid Malignancies Start of enrollment: 2017 Apr 17
Completed
Phase 1
PD-1 Inhibition in Advanced Myeloproliferative Neoplasms Start of enrollment: 2017 Jun 14
Completed
Phase 2
Ruxolitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis. Start of enrollment: 2018 Aug 28
Active, not recruiting
Phase 2
Ruxolitinib in Thrombocythemia and Polycythemia Vera Start of enrollment: 2022 Mar 21
Recruiting
Phase 2
Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis Start of enrollment: 2021 Feb 18
Recruiting
Phase 1, Phase 2
Roles: Contact
I Can Move With Purpose Now! A Pilot Lifestyle Intervention Study in Myeloproliferative Neoplasm Patients Start of enrollment: 2024 Mar 01
Recruiting
Not Applicable
Roles: Contact, Principal Investigator
A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i) Start of enrollment: 2024 Jul 15
Not yet recruiting
Phase 1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

1 citations
Pulmonary Hypertension in Myeloproliferative Neoplasms: New Insights and Unexplored Horizons.
Orly Leiva, Brenda D Garcia, Gabriela Hobbs
American Journal of Respiratory and Critical Care Medicine. 2023-09-01
6 citations
Pulmonary hypertension is associated with poor cardiovascular and hematologic outcomes in patients with myeloproliferative neoplasms and cardiovascular disease.
Orly Leiva, Siyang Ren, Donna Neuberg, Ankeet Bhatt, Andrew Jenkins
International Journal of Hematology. 2023-01-01
43 citations
Quality of life and mood of older patients with acute myeloid leukemia (AML) receiving intensive and non-intensive chemotherapy.
Areej El-Jawahri, Gregory A. Abel, Lara Traeger, Lauren Waldman, Netana Markovitz
Leukemia. 2019-03-28

Journal Articles

Effectiveness of Integrated Palliative and Oncology Care for Patients with Acute Myeloid Leukemia
Areej El-Jawahri, Thomas W Leblanc, Selina M Luger, Bhavana Bhatnagar, Alison R Walker, Amir T Fathi, Andrew M Brunner, Gabriela S Hobbs, Jennifer S Temel, JAMA Oncology

Abstracts/Posters

Pregnancy Outcomes, Risk Factors, and Gestational Cell Count Trends in Pregnant Women with Essential Thrombocythemia and Polycythemia Vera
Gabriela S. Hobbs, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Quality of Life and Psychological Distress in Patients with Acute Myeloid Leukemia (AML)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Phase I Study of the Antibody-Drug Conjugate Brentuximab Vedotin Combined with Re-Induction Chemotherapy in Patients with CD30-Expressing Relapsed/Refractory Acute Mye...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

What Does the Future Look like for Myelofibrosis?November 6th, 2024
Asciminib Study Shows Sustained Improvement, Fewer Adverse EffectsMarch 27th, 2023
Aussie Cancer Researcher Primed for 2023 with Groundbreaking Clinical Trial Data Releases ScheduledJanuary 16th, 2023
Join now to see all

Other Languages

Spanish